Skip to main content
Top

02-12-2016 | Type 1 diabetes | News

News in brief

Antimalarial drug offers means to tackle diabetes

print
PRINT
insite
SEARCH

medwireNews: Researchers find that an existing medication causes α cells to become functionally similar to β cells.

Knowing that loss of the master regulatory transcription factor Arx in mice is sufficient to convert α cells into β cells, the researchers used a cell-based assay to screen molecules for their ability to suppress ARX. This identified an artemisinin – artemether, an antimalarial drug – which suppressed ARX, thus inducing insulin production within α cells, without compromising cell viability.

As reported in Cell, the team confirmed the effects of artemether in zebrafish, mice, and rats, as well as in intact islets from human donors.

In a press statement, study author Stefan Kubicek (CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria) stressed that the long-term effects of artemether treatment remain to be established, and that the newly converted α to β cells will require protection from autoimmunity in patients with type 1 diabetes.

“But we are confident that the discovery of artemisinins and their mode of action can form the foundation for a completely new therapy of type 1 diabetes,” he said.

By Eleanor McDermid

medwireNews is an independent medical news service provided by Springer Healthcare Limited. © Springer Healthcare Ltd; 2016

print
PRINT

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. 

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »